EUVIMEDEUVIMED entdecken
Multizentrische StudieOpen Access · CC BY-NC 4.0

Prognostic value and adjuvant treatment outcomes for the use of the JGOG prognostic model in early-stage intermediate-risk cervical cancer: a Korean Gynecologic Oncology Group study (KGOG 1028)

Uisuk Kim iD, Jaekyung Bae iD, E Sun Paik iD, Myong Cheol Lim iD, Moon-Hong Kim iD, Yun Hwan Kim iD, Seok Ju Seong iD, Dong Hoon Suh iD, Jong-Min Lee iD, Chulmin Lee iD, Chel Hun Choi iD, Sokbom Kang iD

Journal of Gynecologic Oncology · 2026 · 37 (3)

DOI: 10.3802/jgo.2026.37.e59 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift Journal of Gynecologic Oncology, 2026. Verfasst von Uisuk Kim und 11 weiteren Autor:innen. Beteiligte Einrichtung: Center for Gynecologic Cancer, National Cancer Center, Goyang, Korea. Hauptthemen laut MEDLINE: Uterine Cervical Neoplasms. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 24 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

OBJECTIVE: The aim of this study was to validate a new Japanese risk grouping in the Korean population and to identify the group benefit from adjuvant treatment. METHODS: A total of 561 patients with stage IB cervical cancer who underwent radical hysterectomy with lymphadenectomy from 2000 to 2008 across 9 Korean Gynecologic Oncology Group-affiliated institutions were included in this study. Patients had at least one intermediate-risk factor: lymphovascular space invasion, outer one-third of the deep cervical stromal invasion, or a tumor 4 cm or larger. Disease-free survival (DFS) was analyzed based on adjuvant therapies: no treatment, radiation therapy, concurrent chemoradiation therapy or systemic chemotherapy. RESULTS: Patients were classified into 3 groups based on their histologically-incorporated intermediate risk factors. Group 1 included patients with limited risk factors (n=385, 68.6%), group 2 (n=106, 18.9%), and group 3 (n=70, 12.5%) had increasing risk. DFS differed across groups (group 1 vs. group 2, p=0.048; group 2 vs. group 3, p=0.030). Group 1 showed no DFS benefit from adjuvant treatment, while in groups 2 and 3, receiving radiation therapy improved DFS (group 2: adjusted hazard ratio [aHR]=0.09; 95% confidence interval [CI]=0.01-0.80; p=0.031 and group 3: aHR=0.21; 95% CI=0.04-1.08; p=0.047). In group 3, receiving concurrent chemotherapy treatment did not significantly affect DFS compared to radiation alone (aHR=0.84; 95% CI=0.11-6.30; p=0.861). CONCLUSION: This study revealed the prognostic value of histology-incorporated intermediate-risk stratification for early-stage cervical cancer in the Korean population. Unlike the results seen in Japanese populations, adjuvant treatment benefited higher-risk patients in terms of DFS.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Uterine Cervical NeoplasmsFemaleHumansMiddle AgedHysterectomyNeoplasm StagingPrognosisDisease-Free SurvivalRepublic of KoreaAdultLymph Node ExcisionChemotherapy, AdjuvantRadiotherapy, AdjuvantAgedRisk FactorsChemoradiotherapy, AdjuvantRisk AssessmentTreatment Outcome

Stichwörter der Autor:innen

Adjuvant RadiotherapyDisease-Free SurvivalRisk FactorsUterine Cervical Neoplasms

Autor:innen und Institutionen

  • Center for Gynecologic Cancer, National Cancer Center, Goyang, Korea.
  • Department of Obstetrics & Gynecology, Kangbuk Samsung Hospital, Sungkyunkwan University School of Medicine, Seoul, Korea.
  • Department of Obstetrics and Gynecology, Korea Cancer Center Hospital, Korea Institute of Radiological and Medical Sciences, Seoul, Korea.
  • Department of Obstetrics and Gynecology, Ewha Womans University Mokdong Hospital, Ewha Womans University College of Medicine, Seoul, Korea.
  • Department of Obstetrics and Gynecology, CHA Gangnam Medical Center, CHA University, Seoul, Korea.
  • Department of Obstetrics and Gynecology, Seoul National University Bundang Hospital, Seongnam, Korea.

ORCID-Profile: Uisuk Kim, Jaekyung Bae, E Sun Paik, Myong Cheol Lim, Moon-Hong Kim, Yun Hwan Kim, Seok Ju Seong, Dong Hoon Suh, Jong-Min Lee, Chulmin Lee, Chel Hun Choi, Sokbom Kang

Zitieren

APA

Kim, U., Bae, J., Paik, E. S., Lim, M. C., Kim, M. H., Kim, Y. H., Seong, S. J., Suh, D. H., Lee, J. M., Lee, C., Choi, C. H., & Kang, S. (2026). Prognostic value and adjuvant treatment outcomes for the use of the JGOG prognostic model in early-stage intermediate-risk cervical cancer: a Korean Gynecologic Oncology Group study (KGOG 1028). Journal of Gynecologic Oncology, 37(3). https://doi.org/10.3802/jgo.2026.37.e59

Vancouver

Kim U, Bae J, Paik ES, Lim MC, Kim MH, Kim YH, et al. Prognostic value and adjuvant treatment outcomes for the use of the JGOG prognostic model in early-stage intermediate-risk cervical cancer: a Korean Gynecologic Oncology Group study (KGOG 1028). Journal of Gynecologic Oncology. 2026;37(3). doi:10.3802/jgo.2026.37.e59

BibTeX
@article{Kim2026,
  author = {Kim, Uisuk and Bae, Jaekyung and Paik, E Sun and Lim, Myong Cheol and Kim, Moon-Hong and Kim, Yun Hwan and Seong, Seok Ju and Suh, Dong Hoon and Lee, Jong-Min and Lee, Chulmin and Choi, Chel Hun and Kang, Sokbom},
  title = {Prognostic value and adjuvant treatment outcomes for the use of the JGOG prognostic model in early-stage intermediate-risk cervical cancer: a Korean Gynecologic Oncology Group study (KGOG 1028)},
  journal = {Journal of Gynecologic Oncology},
  year = {2026},
  volume = {37},
  number = {3},
  doi = {10.3802/jgo.2026.37.e59}
}
Kostenlos starten →